酒精性肝病的管理
Management of alcoholic liver disease.
作者信息
Lucey Michael R
机构信息
Section of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, H6/516 CSC, 600 Highland Avenue, Madison, WI 53792, USA.
出版信息
Clin Liver Dis. 2009 May;13(2):267-75. doi: 10.1016/j.cld.2009.02.003.
Understanding alcohol addiction and abstinence is key to treating alcoholic liver disease, since abstinence leads to improvement in all forms of alcoholic liver damage. Although pharmacotherapy for alcoholism, using agents such as naltrexone, acamprosate, topiramate, and baclofen, is an exciting field, few studies have included patients with liver disease or cirrhosis. To treat alcoholic liver injury, corticosteroids have become the standard of care in patients with severe alcoholic hepatitis. In contrast, the role of pharmacotherapy to treat alcoholic fibrosis is unclear, with failure to observe a benefit in randomized, placebo-controlled clinical trials of colchicine, S-adenosylmethionine (SAMe), or phosphatidylcholine. Liver transplantation remains an option in selected patients with life-threatening alcoholic liver disease.
了解酒精成瘾和戒酒是治疗酒精性肝病的关键,因为戒酒可改善各种形式的酒精性肝损伤。尽管使用纳曲酮、阿坎酸、托吡酯和巴氯芬等药物进行酒精成瘾的药物治疗是一个令人兴奋的领域,但很少有研究纳入肝病或肝硬化患者。为了治疗酒精性肝损伤,皮质类固醇已成为重症酒精性肝炎患者的标准治疗方法。相比之下,药物治疗在治疗酒精性肝纤维化中的作用尚不清楚,在秋水仙碱、S-腺苷甲硫氨酸(SAMe)或磷脂酰胆碱的随机、安慰剂对照临床试验中未观察到益处。肝移植仍然是某些患有危及生命的酒精性肝病患者的一种选择。